(Q33811941)

29 July 2017

1 reference

title

Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches (English)

1 reference

29 July 2017

1 reference

1 reference

1 reference

Screnci D

1

1 reference

29 July 2017

McKeage MJ

series ordinal

2

1 reference

29 July 2017

publication date

1 October 1999

1 reference

Journal of Inorganic Biochemistry

29 July 2017

published in

1 reference

29 July 2017

volume

77

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

105-110

1 reference

Improved treatment for cervical cancer--concurrent chemotherapy and radiotherapy

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Peripheral sensory neuropathy and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

The course of neuropathy after cessation of cisplatin treatment, combined with Org 2766 or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Progressive paresthesias after cessation of therapy with very high-dose cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Long-term sequelae of treatment for testicular germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Carboplatin: the clinical spectrum to date

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Oxaliplatin in practice

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

A randomized trial of carboplatin versus iproplatin in untreated advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Evaluation of cis-diamminedichloroplatinum (II) (cisplatin) neurotoxicity in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Putative neurotrophic factors in the protection of cisplatin-induced peripheral neuropathy in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Neurotrophin‐3 reverses experimental cisplatin‐induced peripheral sensory neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Nerve growth factor prevents experimental cisplatin neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Examination of distal involvement in cisplatin-induced neuropathy in man

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Stereoselective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-deriv

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Comparative neurotoxicity of oxaliplatin, ormaplatin, and their biotransformation products utilizing a rat dorsal root ganglia in vitro explant culture model.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Effects of the cytostatic drug cis-platinum on the developing neocortex of the mouse.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Influence of cis-dichlorodiammineplatinum on the structure of the immature rat cerebellum.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Morphometric analysis of cisplatin-induced neurite outgrowth in N1E-115 neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Effect of cisplatin and ACTH4-9 on neural transport in cisplatin induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Cisplatin-associated neurotoxicity: can it be prevented?

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Evaluation by somatosensory evoked potentials of the neurotoxicity of cisplatin alone or in combination with glutathione

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Neurotrophin-4/5, brain-derived neurotrophic factor, and neurotrophin-3 promote survival of cultured vestibular ganglion neurons and protect them against neurotoxicity of ototoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Protection against beta-amyloid toxicity in primary neurons by paclitaxel (Taxol)

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Taxol protects against calcium-mediated death of differentiated rat pheochromocytoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

Taxol stabilizes [Ca2+]i and protects hippocampal neurons against excitotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0162-0134%2899%2900135-X

7 January 2021

10.1016/S0162-0134(99)00135-X

Identifiers

DOI

1 reference

29 July 2017

1 reference